Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells · developed by Nurix Therapeutics
De-TIL-0255 is an autologous tumor-infiltrating lymphocyte cell therapy, made from a patient's own lymphocytes taken from tumor tissue. It is studied in platinum-resistant ovarian cancer, endometrial cancer and cervical cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05107739 | Phase 1 | Platinum-resistant Ovarian Cancer | Terminated | NRIX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cervical CancerEndometrial CancerPlatinum-resistant Ovarian Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NRIX page.
See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NRIX catalysts and pipeline →